Fig. 2

Health-related quality of life in our TSC cohort compared with other cohorts with epilepsy. A: Comparison of health-related quality of life (HRQoL), as assessed by the Quality of Life in Epilepsy Inventory-31 items (QOLIE-31) between a study on patients with drug-refractory mesial temporal lobe epilepsy and individuals from our tuberous sclerosis complex (TSC) cohort with active epilepsy (defined as experiencing seizures within the last 12 months). The TSC patients in our cohort demonstrated a lower overall health status compared with temporal lobe epilepsy patients, as measured by the visual analogue scale (VAS) component of the QOLIE-31. Fatigue was higher among TSC patients than temporal lobe epilepsy patients. B: Comparison of patients with TSC, both with and without epilepsy, between the TOSCA registry and our overall cohort. The QOLIE-31 overall quality of life subscore was significantly worse in the TOSCA cohort, seizure worry was higher, emotional well-being was worse, and medication effects were higher among the TOSCA cohort compared with our cohort, with all other categories demonstrating similar values. #Standard deviation for the VAS scale of the questionnaire was not reported by Jansen et al. Independent samples t-tests, * = p < 0.05, ** = p < 0.01, *** = p < 0.001